Browse the preliminary programme and build a personalised schedule for the congress.

Browsing Over 244 Presentations

101.1 - HCC guidelines - what is new?

EBIR
Yes
Presenter:
  • M. Varela (Oviedo, ES)
Learning Objectives:
1. To describe recent updates in international guidelines for classification of HCC
2. To learn about validation of staging systems
3. To discuss the limitations of HCC classification systems in clinical practice

101.2 - Percutaneous ablation: best indication and which energy

EBIR
Yes
Presenter:
  • A. Hocquelet (Lausanne, CH)
Learning Objectives:
1. To learn about the different ablative techniques and approaches for HCC
2. To understand the advantages and disadvantages of each technology and the reported clinical data
3. To discuss the criteria for optimal patient selection

101.3 - Radioembolisation: who is a good candidate after the new classification

EBIR
Yes
Presenter:
  • J. Ricke (Munich, DE)
Learning Objectives:
1. To describe the results of radioembolisation in recent clinical trials
2. To understand the proposed changes in treatment algorithms
3. To discuss the criteria for optimal patient selection from an IR perspective

101.4 - Scientific paper

Presenter:
  • M. Ronot (Clichy, FR)

101.5 - Intermediate stage: what are the indications for combined IO therapies?

Presenter:
  • R. Lencioni (Pisa, IT)
Learning Objectives:
1. To describe the spectrum of clinical scenarios included in the intermediate stage
2. To understand the potential of offering cure to a subset of intermediate patients by using combined treatment approaches
3. To discuss the potential benefit of combining interventional therapies and novel systemic agents

101.6 - HCC and Immunotherapy

EBIR
Yes
Presenter:
  • H. Kl├╝mpen (Amsterdam, NL)
Learning Objectives:
1. To understand the basic concepts of immuno-oncology in the specific setting of HCC treatment
2. To discuss recent clinical data and the on-going investigation
3. To understand the future perspectives of immuno-oncology in the management of HCC

201.1 - Immune alterations in solid tumours

Presenter:
  • W. H. Fridman (Paris, FR)
Learning Objectives:
1. To understand the role of immunity in normal physiology
2. To understand mechanisms of immune escape in cancer
3. To learn about prognosis immunity markers in cancer subtypes

201.2 - Immune checkpoint inhibitors - how do they work?

Presenter:
  • A. Digklia (Lausanne, CH)
Learning Objectives:
1. To learn about mechanisms of action for available immune checkpoint inhibitors
2. To learn about the added value of combination therapies in renal cell carcinomas
3. To better understand side effects of ICI

201.3 - Immune response: the role of the tumour

Presenter:
  • G. Malouf (Strasbourg, FR)
Learning Objectives:
1. To understand the crosstalk between genetic alterations in the tumours and immune alterations
2. To understand how to infer immune-cell infiltrate from transcriptomic data
3. To understand predictive tumour markers associated with response to immune checkpoints inhibitors

201.4 - Immune response: the role of the microenvironment

Presenter:
  • C. Ottensmeier (Southampton, GB)
Learning Objectives:
1. To understand role of TIL
2. To learn about the link between immunity and response to immune checkpoint inhibitors
3. To learn about future strategies for targeting immune microenvironment

201.5 - Mechanisms of priming immune response using local treatment

Presenter:
  • M. Ahmed (Boston, US)
Learning Objectives:
1. To understand the concept of priming
2. To learn about old strategies used for priming
3. To understand novel strategies for priming immune response

202.1 - Ultrasound fusion guidance

Presenter:
  • L. Solbiati (Rozzano, IT)
Learning Objectives:
1. To learn about the latest developments in fusion imaging technology
2. To understand the limitations of ultrasound fusion imaging for the monitoring of ablation
3. To appreciate the current evidence of ultrasound fusion imaging in IO for HCC and metastases